Oxford Developed Covid Vaccine, Then Scholars Clashed Over Money

An early deal with Merck was scotched for fear poor countries would be left out; now the university could make over $100 million with AstraZeneca if the technology succeeds.

https://www.wsj.com/articles/oxford-developed-covid-vaccine-then-scholars-clashed-over-money-11603300412?fbclid=IwAR1DXmkBHLA7ybIHoAc_Wf8_ERHq_IPHACaJTj23gHYFBZhIi180r-jGGVA

Expedited access for COVID-19 related IP - Oxford University Innovation

The COVID-19 pandemic demands an urgent and unprecedented response. University research and expertise is critical ...

https://innovation.ox.ac.uk/technologies-available/technology-licensing/expedited-access-covid-19-related-ip/

無法取得資料

https://healthpolicy-watch.news/ip-not-the-main-barrier-to-equitable-vaccine-rollout-say-two-leading-pharma-execs-at-who-press-conference/

Subscribe to read | Financial Times

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

https://www.ft.com/content/c474f9e1-8807-4e57-9c79-6f4af145b686

Waiving patents alone won't solve COVID-19 vaccine access: developers

Waiving intellectual property rights will not be enough to resolve COVID-19 vaccine access issues, the developers of the Oxford/Astrazeneca and the Pfizer/BioNTech vaccines said on Monday, ahead of a

https://www.reuters.com/article/us-health-coronavirus-who-ip-idUSKBN2B0269

資料佐證

Oxford Developed Covid Vaccine, Then Scholars Clashed Over Money

Expedited access for COVID-19 related IP - Oxford University Innovation

Subscribe to read | Financial Times

Waiving patents alone won't solve COVID-19 vaccine access: developers